Intensive Behavioral Therapy (IBT)

Intensive behavioral therapy for obesity is structured, repeated counseling on eating and activity, delivered face to face by a clinician, on a schedule tight enough that the habits have a chance to stick. It is not a single nutrition consult. Medicare defines it precisely in a national coverage determination, and that definition is the one most insurers echo.

The schedule under that determination, for beneficiaries with a BMI of 30 or higher, runs: one visit every week for the first month, one every other week for months two through six, and one a month for months seven through twelve — with the second half contingent on a reassessment at the six-month mark showing at least 3 kg of weight loss. The counseling itself is meant to follow the five-A framework the U.S. Preventive Services Task Force uses: assess, advise, agree, assist, arrange.

IBT matters in a GLP-1 conversation for two reasons. Some prior-authorization criteria ask for documented participation before approving a weight-management drug, so the visits become a paperwork prerequisite. And the trials say the two are additive, not redundant. STEP 3 paired semaglutide 2.4 mg with intensive behavioral therapy in 611 adults and reported a mean body-weight change of -16.0% versus -5.7% on placebo at week 68, with 55.8% of the semaglutide group losing at least 15%. Note that the placebo group also got the full behavioral program — and still lost 5.7%.

The common confusion is reading IBT as the consolation prize you are offered instead of medication. In the trial design it is the floor both groups stand on. Our STEP 3 deep dive and SURMOUNT-3 page show the same pattern with tirzepatide after a lifestyle lead-in.

Worth asking your clinician: whether your plan requires documented behavioral counseling before it will approve Wegovy or Zepbound, who in the practice is qualified to deliver and bill it, and whether visits can be grouped or delivered by telehealth. Our prior-authorization letter generator helps document it.